This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ETF Market Outlook & Picks for 2021
by Neena Mishra
Two ETF experts share their market outlook and top picks for 2021.
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
by Sweta Killa
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
ETF Sectors to Bet on Positive Vaccine News
by Sweta Jaiswal, FRM
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies
by Sweta Jaiswal, FRM
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?
by Sweta Jaiswal, FRM
Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.
Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.
Red Hot ETF Areas Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
Let's check out some ETF areas that will remain solid investment picks even as the coronavirus cases show a sharp spike.
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Biotech ETFs to Gain on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine
by Sweta Jaiswal, FRM
Moderna plans to begin the Phase 3 study of mRNA-1273 this month.
Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.
3 Hot Sector ETFs to Tide Over the Coronavirus Crisis in Q3
by Sweta Jaiswal, FRM
Here we highlight three sectors that are sizzling with investing opportunities as the second wave of the outbreak is gathering steam.
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen
by Sweta Jaiswal, FRM
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
How Are Biotech ETFs Reacting to Coronavirus Treatment News?
by Sweta Jaiswal, FRM
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
Biotech ETFs Soaring on COVID-19 Vaccine Progress
by Sweta Jaiswal, FRM
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure
by Sweta Jaiswal, FRM
Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.
Bull Market Turns 11: 5 ETF Winners
by Sweta Killa
We have presented a bunch of five top-performing ETFs of the 11-year bull market that will continue to outperform in the coming months given that these have a solid Zacks Rank.
4 Sector ETF Winners of Bull Market Look Resilient to Virus
by Sanghamitra Saha
These sector ETFs emerged winners in the 11-year old bull market and may survive despite the coronavirus scare.
ETFs to Play as Goldman Lowers US Q1 GDP Outlook
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can tap as aggravating coronavirus outbreak lead to a cut in U.S. GDP growth forecast.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?